Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist™, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions
We conducted a randomized, double-blind trial to evaluate the safety and tolerability of a live attenuated cold adapted trivalent intranasal influenza vaccine, FluMist™, compared with intranasal placebo when given in addition to a licensed trivalent injected inactivated influenza vaccine (TIV). The...
Gespeichert in:
| Veröffentlicht in: | Vaccine 1999-04, Vol.17 (15), p.1905-1909 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1909 |
|---|---|
| container_issue | 15 |
| container_start_page | 1905 |
| container_title | Vaccine |
| container_volume | 17 |
| creator | Jackson, Lisa A. Holmes, Sandra J. Mendelman, Paul M. Huggins, Linda Cho, Iksung Rhorer, Janelle |
| description | We conducted a randomized, double-blind trial to evaluate the safety and tolerability of a live attenuated cold adapted trivalent intranasal influenza vaccine, FluMist™, compared with intranasal placebo when given in addition to a licensed trivalent injected inactivated influenza vaccine (TIV). The study population consisted of persons 65 years of age and older with chronic cardiovascular or pulmonary conditions or diabetes mellitus. During the 7 days post-vaccination, sore throat was reported on at least one day by 15% (15/100) of FluMist™ recipients compared with 2% (2/100) of intranasal placebo recipients (
p=0.001). No other reactogenicity symptom was statistically associated with receipt of FluMist™. Among this group, FluMist™ was safe and well tolerated when administered with TIV. |
| doi_str_mv | 10.1016/S0264-410X(98)00471-X |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69711560</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X9800471X</els_id><sourcerecordid>69711560</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-1bc53d8834f780d6e93486e92d8f165053b848b56502454d985c1101d211a1073</originalsourceid><addsrcrecordid>eNqFUcFu1DAQtRCIbgufAPIBIZAa8CRx4pwQqiggFXEoSHuzvPZENco6i-0sKud-CX_Db_AlzG5WFHHhYs9I772ZeY-xRyBegIDm5aUom7qoQSyfdeq5EHULxfIOW4Bqq6KUoO6yxR_IETtO6YsQQlbQ3WdHIEpopVIL9vPS9Jiv-dhzw3P0WzNgyHzwW-QmZwyTyei4DzmaYJIZqOyHCcN3w7fGWh_wlJ8P0wef8q-bH6fcuLUP1GDc06h3Pvsx8DzyjYkkjpFUbkf5YGymZh7zj_aOlTD4MSb-zecrbq_iGLzla3Teko4dw6yfHrB7vRkSPjz8J-zz-ZtPZ--Ki49v35-9vihs1YlcwMrKyilV1X2rhGuwq2pFb-lUD40kh1aqVitJZVnL2nVKWiDHXQlgQLTVCXs6627i-HXClPXaJ4vDYAKOU9JN1wLIRhBQzkAbx5Qi9noT_drEaw1C7zLU-wz1LiDdKb3PUC-J9_gwYFrRmX-x5tAI8OQAMIk86CkZ69MtrlVKlLtFX80wJDe2HqNO1mOw5FxEm7Ub_X82-Q3KE762</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69711560</pqid></control><display><type>article</type><title>Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist™, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Jackson, Lisa A. ; Holmes, Sandra J. ; Mendelman, Paul M. ; Huggins, Linda ; Cho, Iksung ; Rhorer, Janelle</creator><creatorcontrib>Jackson, Lisa A. ; Holmes, Sandra J. ; Mendelman, Paul M. ; Huggins, Linda ; Cho, Iksung ; Rhorer, Janelle</creatorcontrib><description>We conducted a randomized, double-blind trial to evaluate the safety and tolerability of a live attenuated cold adapted trivalent intranasal influenza vaccine, FluMist™, compared with intranasal placebo when given in addition to a licensed trivalent injected inactivated influenza vaccine (TIV). The study population consisted of persons 65 years of age and older with chronic cardiovascular or pulmonary conditions or diabetes mellitus. During the 7 days post-vaccination, sore throat was reported on at least one day by 15% (15/100) of FluMist™ recipients compared with 2% (2/100) of intranasal placebo recipients (
p=0.001). No other reactogenicity symptom was statistically associated with receipt of FluMist™. Among this group, FluMist™ was safe and well tolerated when administered with TIV.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/S0264-410X(98)00471-X</identifier><identifier>PMID: 10217588</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Administration, Intranasal ; Aged ; Biological and medical sciences ; Body Temperature ; Cardiovascular Diseases ; Chronic Disease ; Diabetes Mellitus ; Double-Blind Method ; Epidemiology. Vaccinations ; Female ; Fundamental and applied biological sciences. Psychology ; General aspects ; Humans ; Infectious diseases ; Influenza vaccine ; Influenza Vaccines - administration & dosage ; Influenza Vaccines - adverse effects ; Injections ; Lung Diseases ; Male ; Medical sciences ; Microbiology ; Pharyngitis - etiology ; Prospective Studies ; Time Factors ; Vaccination ; Vaccine safety ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies ; Vaccines, Attenuated - administration & dosage ; Vaccines, Attenuated - adverse effects ; Vaccines, Inactivated - administration & dosage ; Vaccines, Inactivated - adverse effects ; Virology</subject><ispartof>Vaccine, 1999-04, Vol.17 (15), p.1905-1909</ispartof><rights>1999 Elsevier Science Ltd</rights><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-1bc53d8834f780d6e93486e92d8f165053b848b56502454d985c1101d211a1073</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X9800471X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1788027$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10217588$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jackson, Lisa A.</creatorcontrib><creatorcontrib>Holmes, Sandra J.</creatorcontrib><creatorcontrib>Mendelman, Paul M.</creatorcontrib><creatorcontrib>Huggins, Linda</creatorcontrib><creatorcontrib>Cho, Iksung</creatorcontrib><creatorcontrib>Rhorer, Janelle</creatorcontrib><title>Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist™, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>We conducted a randomized, double-blind trial to evaluate the safety and tolerability of a live attenuated cold adapted trivalent intranasal influenza vaccine, FluMist™, compared with intranasal placebo when given in addition to a licensed trivalent injected inactivated influenza vaccine (TIV). The study population consisted of persons 65 years of age and older with chronic cardiovascular or pulmonary conditions or diabetes mellitus. During the 7 days post-vaccination, sore throat was reported on at least one day by 15% (15/100) of FluMist™ recipients compared with 2% (2/100) of intranasal placebo recipients (
p=0.001). No other reactogenicity symptom was statistically associated with receipt of FluMist™. Among this group, FluMist™ was safe and well tolerated when administered with TIV.</description><subject>Administration, Intranasal</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Body Temperature</subject><subject>Cardiovascular Diseases</subject><subject>Chronic Disease</subject><subject>Diabetes Mellitus</subject><subject>Double-Blind Method</subject><subject>Epidemiology. Vaccinations</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>General aspects</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Influenza vaccine</subject><subject>Influenza Vaccines - administration & dosage</subject><subject>Influenza Vaccines - adverse effects</subject><subject>Injections</subject><subject>Lung Diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Microbiology</subject><subject>Pharyngitis - etiology</subject><subject>Prospective Studies</subject><subject>Time Factors</subject><subject>Vaccination</subject><subject>Vaccine safety</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</subject><subject>Vaccines, Attenuated - administration & dosage</subject><subject>Vaccines, Attenuated - adverse effects</subject><subject>Vaccines, Inactivated - administration & dosage</subject><subject>Vaccines, Inactivated - adverse effects</subject><subject>Virology</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUcFu1DAQtRCIbgufAPIBIZAa8CRx4pwQqiggFXEoSHuzvPZENco6i-0sKud-CX_Db_AlzG5WFHHhYs9I772ZeY-xRyBegIDm5aUom7qoQSyfdeq5EHULxfIOW4Bqq6KUoO6yxR_IETtO6YsQQlbQ3WdHIEpopVIL9vPS9Jiv-dhzw3P0WzNgyHzwW-QmZwyTyei4DzmaYJIZqOyHCcN3w7fGWh_wlJ8P0wef8q-bH6fcuLUP1GDc06h3Pvsx8DzyjYkkjpFUbkf5YGymZh7zj_aOlTD4MSb-zecrbq_iGLzla3Teko4dw6yfHrB7vRkSPjz8J-zz-ZtPZ--Ki49v35-9vihs1YlcwMrKyilV1X2rhGuwq2pFb-lUD40kh1aqVitJZVnL2nVKWiDHXQlgQLTVCXs6627i-HXClPXaJ4vDYAKOU9JN1wLIRhBQzkAbx5Qi9noT_drEaw1C7zLU-wz1LiDdKb3PUC-J9_gwYFrRmX-x5tAI8OQAMIk86CkZ69MtrlVKlLtFX80wJDe2HqNO1mOw5FxEm7Ub_X82-Q3KE762</recordid><startdate>19990409</startdate><enddate>19990409</enddate><creator>Jackson, Lisa A.</creator><creator>Holmes, Sandra J.</creator><creator>Mendelman, Paul M.</creator><creator>Huggins, Linda</creator><creator>Cho, Iksung</creator><creator>Rhorer, Janelle</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19990409</creationdate><title>Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist™, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions</title><author>Jackson, Lisa A. ; Holmes, Sandra J. ; Mendelman, Paul M. ; Huggins, Linda ; Cho, Iksung ; Rhorer, Janelle</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-1bc53d8834f780d6e93486e92d8f165053b848b56502454d985c1101d211a1073</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Administration, Intranasal</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Body Temperature</topic><topic>Cardiovascular Diseases</topic><topic>Chronic Disease</topic><topic>Diabetes Mellitus</topic><topic>Double-Blind Method</topic><topic>Epidemiology. Vaccinations</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>General aspects</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Influenza vaccine</topic><topic>Influenza Vaccines - administration & dosage</topic><topic>Influenza Vaccines - adverse effects</topic><topic>Injections</topic><topic>Lung Diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Microbiology</topic><topic>Pharyngitis - etiology</topic><topic>Prospective Studies</topic><topic>Time Factors</topic><topic>Vaccination</topic><topic>Vaccine safety</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</topic><topic>Vaccines, Attenuated - administration & dosage</topic><topic>Vaccines, Attenuated - adverse effects</topic><topic>Vaccines, Inactivated - administration & dosage</topic><topic>Vaccines, Inactivated - adverse effects</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jackson, Lisa A.</creatorcontrib><creatorcontrib>Holmes, Sandra J.</creatorcontrib><creatorcontrib>Mendelman, Paul M.</creatorcontrib><creatorcontrib>Huggins, Linda</creatorcontrib><creatorcontrib>Cho, Iksung</creatorcontrib><creatorcontrib>Rhorer, Janelle</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jackson, Lisa A.</au><au>Holmes, Sandra J.</au><au>Mendelman, Paul M.</au><au>Huggins, Linda</au><au>Cho, Iksung</au><au>Rhorer, Janelle</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist™, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>1999-04-09</date><risdate>1999</risdate><volume>17</volume><issue>15</issue><spage>1905</spage><epage>1909</epage><pages>1905-1909</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>We conducted a randomized, double-blind trial to evaluate the safety and tolerability of a live attenuated cold adapted trivalent intranasal influenza vaccine, FluMist™, compared with intranasal placebo when given in addition to a licensed trivalent injected inactivated influenza vaccine (TIV). The study population consisted of persons 65 years of age and older with chronic cardiovascular or pulmonary conditions or diabetes mellitus. During the 7 days post-vaccination, sore throat was reported on at least one day by 15% (15/100) of FluMist™ recipients compared with 2% (2/100) of intranasal placebo recipients (
p=0.001). No other reactogenicity symptom was statistically associated with receipt of FluMist™. Among this group, FluMist™ was safe and well tolerated when administered with TIV.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>10217588</pmid><doi>10.1016/S0264-410X(98)00471-X</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 1999-04, Vol.17 (15), p.1905-1909 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69711560 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Administration, Intranasal Aged Biological and medical sciences Body Temperature Cardiovascular Diseases Chronic Disease Diabetes Mellitus Double-Blind Method Epidemiology. Vaccinations Female Fundamental and applied biological sciences. Psychology General aspects Humans Infectious diseases Influenza vaccine Influenza Vaccines - administration & dosage Influenza Vaccines - adverse effects Injections Lung Diseases Male Medical sciences Microbiology Pharyngitis - etiology Prospective Studies Time Factors Vaccination Vaccine safety Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies Vaccines, Attenuated - administration & dosage Vaccines, Attenuated - adverse effects Vaccines, Inactivated - administration & dosage Vaccines, Inactivated - adverse effects Virology |
| title | Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist™, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T15%3A16%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20of%20a%20trivalent%20live%20attenuated%20intranasal%20influenza%20vaccine,%20FluMist%E2%84%A2,%20administered%20in%20addition%20to%20parenteral%20trivalent%20inactivated%20influenza%20vaccine%20to%20seniors%20with%20chronic%20medical%20conditions&rft.jtitle=Vaccine&rft.au=Jackson,%20Lisa%20A.&rft.date=1999-04-09&rft.volume=17&rft.issue=15&rft.spage=1905&rft.epage=1909&rft.pages=1905-1909&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/S0264-410X(98)00471-X&rft_dat=%3Cproquest_cross%3E69711560%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69711560&rft_id=info:pmid/10217588&rft_els_id=S0264410X9800471X&rfr_iscdi=true |